Aclaris Therapeutics Cash Flow - Annual (NASDAQ:ACRS)

Add to My Stocks
$14.98 $0.07 (0.47%) ACRS stock closing price Sep 18, 2018 (Closing)

The Aclaris Therapeutics cash flow statement is one of the important reports considered by investors doing a fundamental analysis of the company. While its important to look at the Aclaris Therapeutics debt position, the cash flow statement becomes equally important because public companies use accrual accounting. For example, if a company sells a product which gets counted as Aclaris Therapeutics revenue but does not convert to cash because it does not receive payment in the same quarter, it affects the cash position for that period. Aclaris Therapeutics cash flow analysis is possible because this statement breaks down how balance sheet accounts and income statement items affect cash and cash equivalents. Aclaris Therapeutics had cash and cash equivalents of $30.17M at the beginning of the year and $20.2M at year end for 2017. Aclaris Therapeutics saw a outflow of $-55.69M from investing activities for 2017.

View details of Aclaris Therapeutics cash flows for latest & last 10 financial years
show more
Fiscal year is Jan - Dec20172016201520142013
Net Income Cash Flow
-68.52M-48.07M-20.56M-8.51M-5.23M
Depreciation Depletion Amortization Cash-Flow-----
Net Increase (Decrease) in Assets Liabilities-4.25M-1.07M--
Cash From (used in) Discontinued Operations-----
Other Adjustments Net12.59M9.1M1.17M--
Net Cash from (used by) Operating Activities
-54.66M-34.6M-20.36M-7.63M-4.92M
Increase (Decrease) in Prop Plant And Equipment-1.23M-0.23M-0.5M-0.41M-
Acquisition Disposition of Subsidiaires-9.64M----
Increase (Decrease) in Investments-44.81M-61.67M-76.44M-1.36M-4.53M
Other Cash Inflow (Outflow) from Investment Activities-----
Net Cash from (used by) Investment Activities
-55.69M-61.9M-76.95M-1.77M-4.53M
Issuance (Purchase) of Equity Shares100.46M116.82M39.86M10.58M-
Issuance (Repayment) of Debt Securities-0.07M----
Increase (Decrease) in Bank & Other Borrowings-----
Payment of Dividends & Other Cash Distributions-----
Other Cash from (used by) Financing Activities--56.55M--
Net Cash from (used by) Financing Activities
100.38M116.82M96.41M10.58M-
Effect of Exchange Rate Changes on Cash-----
Net Change in Cash & Cash Equivalents
-9.96M20.32M-0.9M1.16M-9.45M
Cash & Equivalents at Beginning of Year30.17M9.85M10.75M9.58M19.04M
Cash & Equivalents at Year End20.2M30.17M9.85M10.75M9.58M
All figures in USD. M: Millions of USD, B: Billions of USD.

Click here to view our Revance financial analysis

Aclaris Therapeutics stock comparison chart provides an easy way to compare the stock price with peers along with details of Aclaris Therapeutics stock price history.
The statement of cash flows can be categorized into three main sections:

  • Aclaris Therapeutics had a Net Change in Cash and Cash Equivalents of $-9.96M for the latest year 2017. If a firm is able to grow its cash, it is considered to be a positive signal and could lead to a jump in the Aclaris Therapeutics stock price, albeit too much cash on hand can imply the company has no or limited avenues for growth in which to invest this cash.
  • Cash Flow from operating activities: Aclaris Therapeutics reported a negative operating cash flow of $-54.66M for 2017 and has seen a decrease from the previous year. Operating cash flow comes from main business activities. Investors look for positive cash flow from recurring operating activities.
  • Cash Flow from investment activities: Aclaris Therapeutics used $-55.69M cash due to investment activities. It includes the use of cash outside of normal day to day activities like buying fixed assets, plant and machinery etc.
  • Inflow of cash in the form of bank loans and shareholders equity, and outflow of cash because of dividend payments, share repurchase payments etc. come under financing activities. The cash generated from these activities was $100.38M for Aclaris Therapeutics.

Key Financial Ratios For Aclaris Therapeutics Cash Flow

Annual Cash Flow Statements For Aclaris Therapeutics Inc Peers

Fibrocell Science cash flow, NOVAN INC cash flow, Revance cash flow